Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZ21T topical cream in healthy volunteers
NCT06888362Phase 1Completed
- Sponsor
- Genzada Pharmaceuticals USA Inc.
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gz17-6.02 in actinic keratosis (AK) (7 cohorts), sponsored by Genzada Pharmaceuticals USA Inc. Primary endpoints: Adverse Events at 7 days, Number of Reported Skin Reactions at 7 days and 5 more. Started Aug 2024; status: completed.
02
Drugs
gz17-6.02
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT06888362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888362.